Nasal Polyposis Market
DelveInsight’s ‘Nasal Polyposis (NP)-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Nasal Polyposis (NP), historical and forecasted epidemiology as well as the Nasal Polyposis (NP) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The NP market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM NP market size from 2019 to 2032. The Report also covers current NP treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2019–2032
Nasal Polyposis (NP) Disease Understanding and Treatment Algorithm
Nasal Polyposis (NP) Overview
Nasal polyposis (NP) is small, benign (Noncancerous) drop-like growths appearing in the mucosa (lining tissues) of the nose and may block the nasal passageway. Nasal polyposis tends to be present on both sides of the nasal cavity. Small nasal polyps may not reflect any symptoms, but the larger growths or groups of nasal polyps can block the nasal passages or lead to breathing problems, a lost sense of smell, and frequent infections. One-sided nasal polyps may need to be investigated further as they might be malignant nasal or sinus tumors. Nasal polyps are a subgroup of chronic rhinosinusitis (CRS). CRS is a condition where the nasal cavity and sinuses are inflamed for more than 4 to 12 weeks. Patients suffering with CRS condition can be progressed into chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic rhinosinusitis without nasal polyposis (CRSsNP). Only a portion of CRS will develop nasal polyposis.
CRSwNP is a potentially debilitating condition in adults that are characterized by inflammation of the nose and paranasal sinuses with the presence of nasal polyps. People with a history of chronic sinus infections, allergic rhinitis, asthma, cystic fibrosis, sensitivity to NSAIDs like ibuprofen and aspirin, and Churg–Strauss syndrome are more prone to get NP.
Patients suffering from NP may experience Chronic nasal congestion, running nose, Postnasal drip, Reduced sense of smell and taste, difficulty in breathing, pressure in the face or forehead area, snoring, sleep apnea, and others.
Nasal Polyposis (NP) Diagnosis
For the diagnosis of nasal polyps, an ENT specialist or any other physician first look into nasal passages with a special lighted instrument known as a nasoscope. The most preferred techniques are confirming the location, size, and severity of polyps nasal endoscopy, and radiological imaging. Further allergy tests and blood tests can be done to determine other disease-related components.
Continued in the report…..
Nasal Polyposis (NP) Treatment
The standard treatment for nasal polyposis includes a combination of pharmacological and surgical approaches depending on individual case assessment. In general, patients are treated medically in the primary care setting before considering surgical procedures. Treatment aims to eliminate or significantly reduce the size of the nasal polyps resulting in relief of nasal obstruction, improvement in sinus drainage, restoration of olfaction and taste. Treatment of any accompanying rhinitis symptoms may also be required. With both treatments, recurrences are common, particularly in patients with asthma who are twice as likely to develop recurrence compared with nonasthmatics.
Presently, for the treatment of nasal polyposis corticosteroids (intranasal and systemic) and biologics (Dupixent, Xolair, and Nucala) can be used. Corticosteroid implants such as Propel and Sinuva are also available to improve the outcomes of surgery and to be used in recurrent nasal polyposis, respectively. In addition anti-histamines, antibiotics, and NSAIDs can be given depending on the patient's need. If the patient does not show improvement by therapeutics agents then surgery can be also performed to remove the polyps.
Some biologics are also preferred treatment options in the NP patient group. Interleukins 4 and 13 may aggravate nasal polyps, and inhibition with dupilumab (Dupixent) has been shown to decrease polyp burden and improve symptoms.
Nasal Polyposis (NP) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of chronic rhinosinusitis (CRS), diagnosed prevalent cases of chronic rhinosinusitis (CRS), diagnosed prevalent cases of nasal polyposis and gender-specific diagnosed prevalent cases of nasal polyposis scenario of Nasal Polyposis (NP) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
- Total prevalent cases of Chronic Rhinosinusitis (CRS) in the 7MM were found to be 69,550,461 in 2021, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 0.44% during the study period.
- The diagnosed prevalent cases of CRS in the 7MM were found to be 17,973,714 in 2021, which are expected to increase at a CAGR of 0.48% for the study period of 2019-2032.
- As per DelveInsight’s estimates, 7MM accounts for 4,358,603 diagnosed prevalent cases of nasal polyposis in 2021, which are expected to increase at a CAGR of 0.50%.
- Among 7MM, the United States has the highest diagnosed cases of nasal polyposis with 2,172,969 cases in 2021. Among these cases, 55% of cases were male (1,195,133 cases).
- In 2021, EU-5 accounts for 1,982,824 diagnosed prevalent cases of nasal polyposis, which will increase by 2032 at a CAGR of 0.24%.
- In EU-5, Germany had the highest diagnosed cases of nasal polyposis with 617,716 cases, followed by the UK with 435,157 cases and France with 432,058 cases, in 2021. While Spain had the least number of cases with 187,246 in 2021.
- In 2021, Japan had 202,810 diagnosed cases of nasal polyposis ranking second-lowest among 7MM. These cases are expected to decrease by 2032 at a CAGR of -0.28% due to decreasing adult population in the country during the forecasted period (2022–2032).
Country-Wise Nasal Polyposis (NP) Epidemiology
The epidemiology segment also provides the Nasal Polyposis (NP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Nasal Polyposis (NP) Drug Chapters
The drug chapter segment of the Nasal Polyposis (NP) report encloses the detailed analysis of Nasal Polyposis (NP) marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Nasal Polyposis (NP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.
Nasal Polyposis (NP) Marketed Drugs
Nucala (Mepolizumab): GlaxoSmithKline
GSK’s Nucala (Mepolizumab) is the first IL-5 therapy approved as an add-on treatment in the US for adults with chronic rhinosinusitis with nasal polyps to target eosinophilic inflammation in adult patients 18 years of age and older with inadequate response to nasal corticosteroids. Nucala got recently approved by US FDA based on positive results from the pivotal Synapse study.
Products detail in the report…
Dupixent (Dupilumab): Sanofi/Regeneron Pharmaceuticals
Dupixent is an interleukin-4 receptor alpha antagonist, indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). Patients with comorbid CRSwNP and asthma are often more difficult to treat, so it is encouraging that Dupixent, which targets key drivers of Type 2 inflammation, may address both conditions in these patients.
Products detail in the report…
Xolair (Omalizumab): Hoffmann-La Roche/Novartis
Xolair (omalizumab) is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation. Omalizumab is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is administered as a subcutaneous (SC) injection and is available in prefilled syringes and vials. Injection form is a lyophilized, white, sterile powder in a 150 mg single-dose vial without preservatives, and prefilled Syringe is available in 75 mg and 150 mg
Products detail in the report…
Nasal Polyposis (NP) Emerging Drugs
Fasenra (benralizumab): AstraZeneca
Fasenra (benralizumab), being developed by AstraZeneca, is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death). Fasenra targets seven diseases beyond respiratory disease. In 2021, the company filed the NDA application in the US and planning to file the dossier in Europe and Japan in 2022.
Products detail in the report…
AstraZeneca in collaboration with Amgen is developing Tezepelumab as a potential human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). TSLP is an epithelial-derived cytokine produced in response to airborne stimuli, such as allergens, viruses, and diesel exhaust. It plays a key role in the initiation and persistence of airway inflammation by activating multiple downstream inflammatory pathways. TSLP expression is elevated in the airways of patients with asthma compared with healthy individuals and in nasal polyp tissue from patients with CRSwNP compared with healthy sinus tissue or that from patients with CRS without NP. Tezepelumab is in Phase III clinical trial for nasal polyps and other indications. The positive response for CRSwNP Tezepelumab was explored from the clinical trials; specifically, Pathway and Navigator, dedicated for the Asthma indication.
Products detail in the report…
CBP-201: Connect Biopharma
CBP-201, discovered internally using Connect Biopharma’s proprietary Immune Modulation Technology Platform, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα). CBP-201 is being investigated for CRSwNP, Atopic dermatitis (AD), and Type 2 inflammation with a focus to show rapid onset and sustained improvements in clinical outcomes with a convenient dosing frequency. The ongoing Phase IIb global clinical trial in CRSwNP is supposed to support the clinical outcomes of atopic dermatitis and asthma.
Products detail in the report…
List to be continued in the report…
Nasal Polyposis (NP) Market Outlook
Regardless of the discovery of biomarkers, the current treatment paradigm revolves around non-biomarker-specific treatment choices. Symptomatic nasal polyposis patients are initially started with intranasal steroids, and the subsequent options remain a short course of oral corticosteroids and then surgical intervention. Recently the market of nasal polyposis welcomed three biologics (Nucala: mepolizumab; Dupixent: dupilumab; Xolair: omalizumab). Experts say biologics are considered before primary surgery, particularly in patients whom conditions like asthma are present simultaneously with CRSwNP, in those for whom surgery is less available, in patients who refuse surgery, and/or patients with a high complication ratio. The use of biologics straightaway after surgery might be considered for patients whose nasal polyps recur a year after the surgery.
For many patients with uncontrolled or severe disease, a combination of sinus surgery and the use of a biologic that is targeted to their precise endotype may be the optimal treatment strategy. However, which surgical approach and which biologics are best for each patient are debates that remain ongoing.
According to DelveInsight, Nasal Polyposis (NP) 7MM is expected to change in the study period 2019–2032.
- The market size of Nasal Polyposis in the seven major markets is expected to increase at approximate Compound Annual Growth Rate (CAGR) of 9.00% for the study period (2019–2032) from USD 1,532 million in 2021 to significant market size by 2032.
- Expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Nasal Polyposis (NP).
- Upcoming therapies such as Fasenra, Tezepelumab, CBP201, Xolair, and Nucala, have the potential to create a significant positive shift in the Nasal Polyposis (NP) market size.
- The United States accounts for the largest market size of Nasal Polyposis (NP), in comparison to EU-5 (Germany, France, Italy, Spain, and the United Kingdom,) and Japan.
- Among the EU-5 countries, Germany had the highest market size, while Spain had the lowest market size of Nasal Polyposis (NP) throughout the study period (2019–2032).
The United States Market Outlook
This section provides the total Nasal Polyposis (NP) market size and; market size by therapies in the United States.
EU-5 Market Outlook
The total Nasal Polyposis (NP) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Nasal Polyposis (NP) market size and market size by therapies in Japan are provided.
Nasal Polyposis (NP) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Nasal Polyposis (NP) market or expected to get launched in the market during the study period 2019–2032. The analysis covers Nasal Polyposis (NP) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Nasal Polyposis (NP) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Nasal Polyposis (NP) emerging therapies.
Reimbursement Scenario in Nasal Polyposis (NP)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Nasal Polyposis (NP) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Nasal Polyposis (NP), explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the Nasal Polyposis (NP) epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Nasal Polyposis (NP) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Nasal Polyposis (NP) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Nasal Polyposis (NP) market.
- The robust pipeline with novel MOA and oral ROA and increasing prevalence will positively drive the Nasal Polyposis (NP) market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Nasal Polyposis (NP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Nasal Polyposis (NP). Launch of emerging therapies will significantly impact the Nasal Polyposis (NP) market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Nasal Polyposis (NP) Report Insights
- Patient Population
- Therapeutic Approaches
- Nasal Polyposis (NP) Pipeline Analysis
- Nasal Polyposis (NP) Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Nasal Polyposis (NP) Report Key Strengths
- 11-Years Forecast
- 7MM Coverage
- Nasal Polyposis (NP) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Nasal Polyposis (NP) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
- What was the Nasal Polyposis (NP) market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Nasal Polyposis (NP) total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Nasal Polyposis (NP) market size during the forecast period (2022–2032)?
- At what CAGR, the Nasal Polyposis (NP) market is expected to grow at the 7MM level during the forecast period (2022–2032)?
- What would be the Nasal Polyposis (NP) market outlook across the 7MM during the forecast period (2022–2032)?
- What would be the Nasal Polyposis (NP) market growth till 2032 and what will be the resultant market size in the year 2032?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
- What is the disease risk, burden and unmet needs of Nasal Polyposis (NP)?
- What is the historical Nasal Polyposis (NP) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of Nasal Polyposis (NP) at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Nasal Polyposis (NP)?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Nasal Polyposis (NP) during the forecast period (2022–2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Nasal Polyposis (NP) along with the approved therapy?
- What are the current treatment guidelines for the treatment of Nasal Polyposis (NP) in the US and Europe?
- What are the Nasal Polyposis (NP) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Nasal Polyposis (NP)?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Nasal Polyposis (NP)?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nasal Polyposis (NP) therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nasal Polyposis (NP) and their status?
- What are the key designations that have been granted for the emerging therapies for Nasal Polyposis (NP)?
- What are the 7MM historical and forecasted market of Nasal Polyposis (NP)?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Nasal Polyposis (NP).
- To understand the future market competition in the Nasal Polyposis (NP) market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Nasal Polyposis (NP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Nasal Polyposis (NP) market.
- To understand the future market competition in the Nasal Polyposis (NP) market.